MLN9708

For research use only. Not for therapeutic Use.

  • CAT Number: I000957
  • CAS Number: 1239908-20-3
  • Molecular Formula: C20H23BCl2N2O9
  • Molecular Weight: 517.12
  • Purity: ≥95%
Inquiry Now

MLN9708 (Cat No.:I000957), also known as ixazomib, is a proteasome inhibitor developed as an anticancer agent. It belongs to the class of boron-containing compounds and is a second-generation proteasome inhibitor derived from bortezomib. MLN9708 selectively and reversibly inhibits the chymotrypsin-like activity of the 20S proteasome, which plays a crucial role in protein degradation and cellular homeostasis. By inhibiting the proteasome, MLN9708 disrupts protein turnover, accumulating misfolded or unwanted proteins and subsequent induction of apoptosis in cancer cells. It has shown efficacy in various hematologic malignancies and solid tumors and has been approved for treating multiple myeloma.


Catalog Number I000957
CAS Number 1239908-20-3
Molecular Formula C20H23BCl2N2O9
Purity ≥95%
Target 20S Proteasome
Solubility DMSO 103 mg/mL; Water <1 mg/mL
Storage -20°C
IC50 3.4 nM (MLN2238)
IUPAC Name (R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
InChI InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1
InChIKey MBOMYENWWXQSNW-AWEZNQCLSA-N
SMILES O=C(O)CC1(OB(OC1=O)C(NC(=O)CNC(=O)C2=CC(Cl)=CC=C2Cl)CC(C)C)CC(=O)O
Reference

<p>
[1]. Kupperman E, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. <br />
[2]. Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. <br />
[3]. Tian Z, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 8;120(19):3958-67.
</p>

Request a Quote